Treatment of paclitaxel combined with oxaliplatinchemotherapy to the non-small cell lung cancer mouse model
- VernacularTitle:紫杉醇联合奥沙利铂对非小细胞肺癌模型小鼠的治疗作用
- Author:
Ning MAO
;
Tao XIONG
- Keywords:
chemotherapy;
non-small cell lung cancer;
cell apoptosis;
programmed cell death 5 (PDCD5);
X-linked inhibitor of apoptosis protein(XIAP)
- From:
Basic & Clinical Medicine
2017;37(9):1303-1307
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effect of paclitaxel plus oxaliplatin chemotherapy to the transplanted non-small cell lung cancer of nude mice and the effect to the apoptosis protein expression of PDCD5 and XIAP with mice model.Methods A tumor-bearing mice were randomly divided into blank group, normal saline group, oxaliplatin group, paclitaxel group, paclitaxel plus oxaliplatin group.The gene expression of PDCD5 and XIAP was assayed by real-time quantitative PCR(q-PCR).The apoptosis related PDCD5 and XIAP protein were detected by Western blot.Finally, the tumor weight of each group was measured for statistical analysis.ResultsThe mRNA expression of PDCD5 was highest and the gene expression of XIAP was lowest in paclitaxel plus oxaliplatin group(P<0.01).The expression of PDCD5 protein was highest and the expression of XIAP protein was lowest in paclitaxel plus oxaliplatin group (P<0.01).Finally, compare the tumor weight of each group, paclitaxel plus oxaliplatin group has the least mass(P<0.01).Conclusions Paclitaxel plus oxaliplatin group chemotherapy significantly increases PDCD5 expression and reduce XIAP expression.Meanwhile, paclitaxel plus oxaliplatin chemotherapy can significantly reduce the tumor weight of happened non-small cell lung cancer.
